natgillin/translations-raw huggingface dataset:
Both regimens were administered once every 3 weeks for 6 cycles. 
Obe shemi so dajali enkrat na 3 tedne 6 ciklusov.
Taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. 
Zdravilo Taxespira je v kombinaciji s prednizonom ali prednizolonom indicirano za zdravljenje bolnikov z metastatskim hormonsko neodzivnim rakom prostate.
The survival rate was 93.7% in the TAC arm and 91.4 % in the FAC arm, at the 8-year follow-up timepoint, and 91.3 % in the TAC arm and 89 % in the FAC arm, at the 10-year follow-up timepoint. 
Po 8 letih spremljanja je bil delež preživetja v kraku TAC 93,7 % in v kraku FAC 91,4 %, po 10 letih spremljanja pa je bil v kraku TAC 91,3 % in v kraku FAC 89 %.
In anthracycline-failure patients, docetaxel was compared to the combination of mitomycin C and vinblastine (12 mg/m² every 6 weeks and 6 mg/m² every 3 weeks). 
Pri bolnicah po neuspelem antraciklinskem zdravljenju so docetaksel primerjali s kombinacijo mitomicina C in vinblastina (12 mg/m2 na 3 tedne).
You must not be given Taxespira 
Zdravila Taxespira ne smete dobiti:
Data from a multicenter open label randomized trial support the use of Taxespira for the adjuvant treatment of patients with operable node-negative breast cancer eligible to receive chemotherapy. 
Podatki multicentričnega, odprtega randomiziranega preskušanja podpirajo uporabo zdravila Taxespira za adjuvantno zdravljenje bolnic z operabilnim rakom dojke z negativnimi bezgavkami, primernih za prejemanje kemoterapije.
This is equivalent to 80 ml of beer or 33 ml of wine. 
To ustreza 80 ml piva ali 33 ml vina.
Vial label 
Nalepka na viali
• flushing, skin reactions, itching 
• zardevanje, kožne reakcije, srbenje
As the benefit observed in patients with 4 + nodes was not statistically significant on DFS and OS, the positive benefit/risk ratio for TAC in patients with 4 + nodes was not fully demonstrated at the final analysis. 
Korist za preživetje brez bolezni in celokupno preživetje pri bolnicah z bezgavkami 4+ ni bila statistično značilna, zato končna analiza ni v celoti potrdila pozitivnega razmerja med koristjo in tveganjem TAC pri bolnicah z bezgavkami 4+.
Stomatitis/mucositis grade 3 First episode: reduce 5-FU dose by 20%. 
Toksičen učinek Prilagoditevodmerka driska 3. stopnje Prvi pojav: zmanjšajte odmerek 5-FU za 20 %.
Patients on the docetaxel arm received docetaxel (T) 75 mg/m2 followed by cisplatin (P) 75 mg/m2 followed by 
Bolniki v kraku z docetakselom so prejeli docetaksel (T) 75 mg/m2, ki mu je sledil cisplatin (P) 75 mg/m2, temu pa 5
General disorders and administration site conditions Infusion site reactions were generally mild and consisted of hyper pigmentation, inflammation, redness or dryness of the skin, phlebitis or extravasation and swelling of the vein. 
Reakcije na mestu infundiranja so bile praviloma blage; obsegale so hiperpigmentacijo, vnetje, pordelost ali suhost kože, flebitis ali ekstravazacijo oz. otekanje vene.
Hazard Ratio: 1.032 [95% CI: 0.876; 1.216] 
razmerje tveganj: 1,032 [95 % IZ: 0,876; 1,216]
Very common (may affect more than 1 in 10 people): 
Zelo pogosto (pojavijo se lahko pri več kot 1 od 10 bolnikov):
• oral candidiasis (thrush) 
• oralna kandidoza (sor)
30-60 minutes every 3 weeks (TCis), docetaxel 75 mg/m2 as a 1 hour infusion in combination with carboplatin (AUC 6 mg/ml.min) over 30-60 minutes every 3 weeks, or vinorelbine (V) 25 mg/m administered over 6-10 minutes on days 1, 8, 15, 22 followed by cisplatin 100 mg/m 2 administered on day 1 of cycles repeated every 4 weeks (VCis). 
Druga je na 3 tedne dobivala docetaksel 75 mg/m 2 v 1-urni infuziji v kombinaciji s karboplatinom (AUC 6 mg/ml•min) v 30-60 minutah, tretja (VCis) pa na 4 tedne vinorelbin (V) 25 mg/m 2 v 6-10 minutah 1., 8., 15. in 22. dan, ki mu je 1. dan ciklusov sledil cisplatin 100 mg/m
Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease. 
Zdravilo Taxespira je v kombinaciji s cisplatinom in 5-fluorouracilom indicirano za zdravljenje bolnikov z metastatskim adenokarcinomom želodca, vključno z adenokarcinomom na gastroezofagealnem prehodu, ki predhodno še niso bili zdravljeni s kemoterapijo za metastatsko bolezen.
For prostate cancer, the premedication is oral dexamethasone 8 mg, 12 hours, 3 hours and 1 hour before the docetaxel infusion (see section 4.2). 
Pri zdravljenju raka prostate je premedikacija peroralni deksametazon 8 mg, 12 ur, 3 ure in 1 uro pred infuzijo docetaksela (prosimo, glejte poglavje 4.2).
For patients who are dosed initially at docetaxel 75 mg/m2 in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is <25,000 cells/mm 
Bolnikom, ki uvodoma dobijo docetaksel v odmerku 75 mg/m2 v kombinaciji s cisplatinom in imajo v predhodnem ciklusu zdravljenja najmanjše število trombocitov < 25.000 celic/mm
• For the treatment of head and neck cancer, Taxespira is administered in combination with cisplatin and 5-fluorouracil. 
• Za zdravljenjeraka glave in vratu se zdravilo Taxespira uporablja v kombinaciji s cisplatinomin 5fluorouracilom.
In addition, physical and chemical in-use stability of the infusion solution prepared with sodium chloride 9 mg/ml (0.9%) or 5% glucose infused solution in non-PVC bags or with 5% glucose in glass bottles has been demonstrated for up to 48 hours when stored between 2°C to 8°C and for up to 
Poleg tega je bilo dokazano, da je infuzijska raztopina med uporabo, če je pripravljena z raztopino natrijevega klorida 9 mg/ml (0,9 %) ali s 5% raztopino glukoze v vrečah, ki ne vsebujejo PVC ali s 5% raztopino glukoze v steklenih steklenicah, kemijsko in fizikalno stabilna 48 ur pri temperaturi od 2-8 °C in do 6 ur, če je shranjena pri temperaturi do 25 °C.
• Induction chemotherapy followed by chemoradiotherapy (TAX324) The safety and efficacy of docetaxel in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a randomized, multicenter open-label, phase III study (TAX324). 
• Indukcijska kemoterapija in nato kemoradioterapija(TAX324) Varnost in učinkovitost docetaksela za indukcijsko zdravljenje bolnikov z lokalno napredovalim skvamoznoceličnim karcinomom glave in vratu (SCCHN) so ocenili v randomiziranem multicentričnem odprtem preskušanju III. faze (TAX324).
At the end of the follow-up period (actual median follow-up time of 10 years and 5 months), no patients had CHF in TAC arm and 1 patient in TAC arm died because of dilated cardiomyopathy and CHF was observed to be ongoing in 1 patient (0.2%) in FAC arm. 
Na koncu spremljanja (dejanski mediani čas spremljanja 10 let in 5 mesecev) ni imela kongestivnega srčnega popuščanja (KSP) nobena bolnica v kraku TAC in 1 bolnica v kraku TAC je umrla zaradi dilatativne kardiomiopatije, še trajajoče KSP pa so zabeležili pri 1 bolnici (0,2 %) v kraku FAC.
Without affecting OS time (docetaxel 15 months vs. doxorubicin 14 months, p = 0.38) or time to progression (docetaxel 27 weeks vs. doxorubicin 23 weeks, p = 0.54), docetaxel increased response rate (52% vs. 37%, p = 0.01) and shortened time to response (12 weeks vs. 23 weeks, p = 0.007). 
Docetaksel ni vplival na celotni čas preživetja (docetaksel 15 mesecev, doksorubicin 14 mesecev, p = 0,38) niti na čas do napredovanja (docetaksel 27 tednov, doksorubicin 23 tednov, p = 0,54), je pa zvečal delež odziva (52 % v prim.
Taxespira concentrate for solution for infusion is a pale yellow to brownish-yellow solution provided in glass vials. 
Zdravilo Taxespira koncentrat za raztopino za infundiranje je bledo rumena do rjavo-rumena raztopina.
6.6 Special precautions for disposal and other handling 
6.6 Posebni varnostni ukrepi za odstranjevanjein ravnanje z zdravilom
The median number of cycles administered per patient was 6 (with a range of 1-16) for the TCF arm compared to 4 (with a range of 1-12) for the CF arm. Time to progression (TTP) was the primary endpoint. 
V kraku s TCF je bilo mediano število ciklusov na bolnika 6 (razpon: od 1 do 16), v kraku s CF pa 4 (razpon: od 1 do 12).
• Induction chemotherapy followed by radiotherapy (TAX 323) For the induction treatment of inoperable locally advanced squamous cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel is 75 mg/m 2 as a 1 hour infusion followed by cisplatin 75 mg/m2 over 1 hour, on day one, followed by 5-fluorouracil as a continuous infusion at 750 mg/m2 per day for five days. 
• Indukcijska kemoterapija in nato radioterapija (TAX 323) Za indukcijsko zdravljenje inoperabilnega lokalno napredovalega skvamoznoceličnega karcinoma glave in vratu (SCCHN - squamous cell carcinoma of the head and neck), je priporočeni odmerek docetaksela 75 mg/m v obliki enourne infuzije, ki ji sledi cisplatin 75 mg/m 2, infundiran 1 uro dolgo prvega dne, temu pa sledi 5-fluorouracil v obliki neprekinjene infuzije v odmerku 750 mg/m 2 na dan pet dni.
Docetaxel + Cis + 5-FU n = 255 
Docetaksel + Cis +5-FU n = 255
G3/4 AST increased 
zvečanje AST S3/4
• Induction chemotherapy followed by chemoradiotherapy (TAX 324) 
• Indukcijska kemoterapija in nato kemoradioterapija(TAX 324)
Patients with hepatic impairment Based on pharmacokinetic data with docetaxel at 100 mg/m2 as single agent, patients who have both elevations of transaminase (ALT and/or AST) greater than 1.5 times the upper limit of the normal range (ULN) and alkaline phosphatase greater than 2.5 times the ULN, the recommended dose of 2 (see sections 4.4 and 5.2). 
Bolniki z okvaro jeter Glede na farmakokinetične podatke o monoterapiji z docetakselom v odmerku 100 mg/m2 je priporočljivi odmerek docetaksela za bolnike, ki imajo transaminazi (ALT, AST ali obe) zvišani nad 1,5-kratno zgornjo mejo normalnega območja (ULN) in alkalno fosfatazo nad 2,5-kratno ULN, 75 mg/m2 (glejte poglavji 4.4 in 5.2).
In addition, physical and chemical in-use stability of the infusion solution prepared as recommended in non-PVC bags or bottles has been demonstrated up to 48 hours when stored between 2°C to 8°C, and for up to 6 hours when stored below 25°C. 
Poleg tega je bilo dokazano, da je skladno spriporočili pripravljena infuzijska raztopina v vrečkah, ki ne vsebujejo PVC, ali v steklenicah med uporabo kemijsko in fizikalno stabilna 48 ur pri temperaturi od 2-8 °C in do 6 ur, če je shranjena pri temperaturi do 25 °C.
Single use vials. 
Viale za enkratno uporabo.
Vials containing 20 mg/1 ml, 80 mg/4 ml, 120 mg/6 ml, 140 mg/7 ml and 160 mg/8 ml are available in packs containing a single vial. 
Viale, ki vsebujejo 20 mg/1 ml, 80 mg/4 ml,120 mg/6 ml, 140 mg/7 ml in 160 mg/8 ml so na voljo v škatlah, ki vsebujejo po eno vialo.
• 1,312 and 121 patients who received 100 mg/m2 and 75 mg/m2 of docetaxel as a single agent 
• 1.312 bolnikih, ki so v monoterapiji prejemali 100 mg/m² docetaksela, 121 pa jih je prejemalo
This is equivalent to 10 ml of beer or 4 ml of wine. 
To ustreza 10 ml piva ali 4 ml vina.
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as ciclosporine, ketoconazole and erythromycin. 
Študije in vitro so pokazale, da lahko presnovo docetaksela spremeni sočasna uporaba zdravil, ki inducirajo ali inhibirajo citokrom P450-3A ali se z njim presnavljajo (in ga tako lahko kompetitivno inhibirajo), kot so ciklosporin, ketokonazol in eritromicin.Zato je med sočasnim zdravljenjem s temi zdravili potrebna previdnost, saj obstaja možnost pomembnega medsebojnega delovanja.
160mg/8 ml contains 8 ml of concentrate. 
160 mg/8 ml vsebuje 8 ml koncentrata.
• nasal drainage; inflammation of the throat and nose; cough 
• izcedek iz nosu, vnetje žrela in nosu, kašelj
If Taxespira concentrate should come into contact with mucous membranes, wash immediately and thoroughly with water. 
Če pride koncentrat zdravila Taxespira v stik s sluznicami, jih je treba takoj in temeljito umiti z vodo.
G3/4 Blood alkaline phosphatase increased 
zvečanje alkalne fosfataze v krvi S3/4
• Induction chemotherapy followed by radiotherapy (TAX323) The safety and efficacy of docetaxel in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a phase III, multicenter, open-label, randomized study (TAX323). 
• Indukcijska kemoterapija in nato radioterapija (TAX323) Varnost in učinkovitost zdravila docetaksel za indukcijsko zdravljenje bolnikov s skvamoznoceličnim karcinomom glave in vratu (SCCHN) so ocenjevali v multicentrični odprti randomizirani študiji faze III (TAX323).
140mg/7 ml contains 7 ml of concentrate. 
140 mg/7 ml vsebuje 7 ml koncentrata.
At the median follow-up time of 77 months, OS was longer in the TAC arm with TAC-treated patients having a 24% reduction in the risk of death compared to FAC (hazard ratio = 0.76, 95% CI (0.46-1.26, p = 0.29). 
Po mediano 77 mesecih spremljanja je bilo tudi celokupno preživetje v kraku TAC daljše: tveganje za smrt je bilo med prejemnicami TAC za 24 % manjše kot med prejemnicami FAC (razmerje ogroženosti = 0,76, 95 % IZ 0,46-1,26, p = 0,29).
5.1 Pharmacodynamic properties 
5.1 Farmakodinamičnelastnosti
Therefore, the recommended dose of docetaxel in those patients with elevated liver function test (LFTs) is 75 mg/m2 and LFTs should be measured at baseline and before each cycle (see section 4.2). 
Zato je pri bolnikih z zvišanimi vrednostmi testov jetrne funkcije priporočeni odmerek docetaksela 75 mg/m2, teste jetrne funkcije pa je treba opraviti na začetku in pred vsakim ciklusom zdravljenja (glejte poglavje 4.2).
20mg/1 ml contains 1 ml of concentrate. 
20 mg/1 ml vsebuje 1 ml koncentrata.
256 patients were randomised to treatment with docetaxel alone (100 mg/m2 as a 1 hour intravenous infusion every 3 weeks). 
256 bolnic so randomizirali na zdravljenje z docetakselom samim (100 mg/m2 v 1-urni intravenski infuziji na
There was less use of morphinic analgesic (p <0.01), non-morphinic analgesics (p <0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p <0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC. 
Bolniki, zdravljeni z docetakselom v odmerku 75 mg/m2, so rabili manj morfinskih analgetikov (p < 0,01), nemorfinskih analgetikov (p < 0,01), drugih z boleznijo povezanih zdravil (p = 0,06) in radioterapije (p < 0,01) kot tisti, ki so bili deležni najboljše podporne oskrbe.
Thrombocytopenia (G3/4: 0.6%); Febrile neutropenia 
trombocitopenija, (S3/4: 0,6 %), febrilna nevtropenija
Ear and labyrinth disorders Rare cases of ototoxicity, hearing impaired and/or hearing loss have been reported. 
Ušesne bolezni, vključno z motnjami labirinta Opisani so bili redki primeri ototoksičnosti, okvar sluha in/ali poslabšanja sluha.
For prostate cancer, given the concurrent use of prednisone or prednisolone the recommended premedication regimen is oral dexamethasone 8 mg, 12 hours, 3 hours and 1 hour before the docetaxel infusion (see section 4.4). 
Pri zdravljenju raka prostate, v primeru sočasne uporabe prednizona ali prednizolona, je priporočena premedikacija peroralni deksametazon 8 mg, 12 ur, 3 ure in 1 uro pred infuzijo docetaksela (glejte poglavje 4.4).
In chemotherapy naïve patients treated for non-small cell lung cancer, the recommended dose regimen is docetaxel 75 mg/m immediately followed by cisplatin 75 mg/m over 30-60 minutes. 
Pri bolnikih z nedrobnoceličnim pljučnim rakom, ki še niso bili zdravljeni s kemoterapijo, je priporočena shema odmerjanja docetaksel v odmerku 75 mg/m2, ki mu takoj sledi cisplatin v odmerku 75 mg/m apliciran 30-60 minut.
50 mg/m2 (TAC arm), or doxorubicin 50 mg/m 2 followed by fluorouracil 500 mg/m2 (FAC arm). 
mg/m2, ki sta mu sledila fluorouracil 500 mg/m2 in ciklofosfamid 500 mg/m2 (krak FAC).
In alkylating-failure patients, docetaxel was compared to doxorubicin (75 mg/m² every 3 weeks). 
Pri bolnicah z neuspelim alkilirajočim zdravljenjem so docetaksel primerjali z doksorubicinom (75 mg/m na 3 tedne).
• ventricular arrhythmia or ventricular tachycardia (manifested as irregular and/or rapid heartbeat, 
• prekatne motnje srčnega ritma ali prekatna tahikardija (ki se kaže z nerednim in/ali hitrim bitjem srca, zelo težkim dihanjem, omotico in/ali omedlevico).
75 mg/m2, as a 1- to 3-hour infusion (both on day 1 only), followed by 5-fluorouracil 750 mg/m2 per day given as a 24-hour continuous infusion for 5 days, starting at the end of the cisplatin infusion. 
urni infuziji (oboje samo 1. dan); temu sledi 5-fluorouracil 750 mg/m2 na dan v 24-urni stalni infuziji 5 dni, z začetkom ob koncu infuzije cisplatina.
Taxespira in combination with capecitabine 
Zdravilo Taxespira v kombinaciji s kapecitabinom
In combination with cisplatin and 5-fluorouracil for the treatment of patients with gastric adenocarcinoma, the pivotal clinical study excluded patients with ALT and/or AST >1.5 × ULN associated with alkaline phosphatase >2.5 × ULN, and bilirubin >1 x ULN; for these patients, no dose-reductions can be recommended and docetaxel should not be used unless strictly indicated. 
V ključni klinični študiji docetaksela v kombinaciji s cisplatinom in 5-fluorouracilom pri bolnikih z adenokarcinomom želodca so izključili bolnike z ALT in/ali AST > 1,5 x ULN ter hkrati alkalno fosfatazo > 2,5 x ULN in bilirubinom > 1 x ULN; pri teh bolnikih ni mogoče priporočiti zmanjšanja odmerka in docetaksela se ne sme uporabljati, če ni strogo indiciran.
140mg/7 ml Each 7 ml vial of concentrate contains 3.5 ml of ethanol anhydrous (2765 mg). 
140 mg/7 ml Ena 7 ml viala koncentrata vsebuje 3,5 ml brezvodnega etanola (2765 mg).
For breast, non-small cell lung, gastric, and head and neck cancers, premedication consisting of an oral corticosteroid, such as dexamethasone 16 mg per day (e.g. 8 mg BID) for 3 days starting 1 day prior to docetaxel administration, unless contraindicated, can be used (see section 4.4). 
Pri zdravljenju raka dojke, nedrobnoceličnega pljučnega raka, raka želodca ter raka glave in vratu lahko kot premedikacijo dajemo peroralne kortikosteroide, kot je deksametazon 16 mg na dan (npr. 8 mg dvakrat dnevno) v trajanju treh dni, in sicer 1 dan pred aplikacijo docetaksela, razen v primeru kontraindikacij (prosimo, glejte poglavje 4.4).
Acute respiratory distress syndrome and cases of interstitial pneumonia/pneumonitis, interstitial lung disease, pulmonary fibrosis and respiratory failure sometimes fatal have rarely been reported. 
Bolezni dihal, prsnega koša in mediastinalnega prostora V redkih primerih so bili opisani akutni respiracijski distres sindrom in primeri intersticijske pljučnice/pnevmonitis, intersticijska bolezen pljuč, pljučna fibroza in dihalna odpoved, ki so bili včasih usodni.
Description of selected adverse reactions for adjuvant therapy with Taxespira 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer 
Opis izbranih neželenih učinkov adjuvantnega zdravljenja z zdravilom Taxespira 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805)
Dizziness; Headache (G3/4: <1%); Neuropathy peripheral 
Bolezni živčevja omotica, glavobol (S3/4: < 1 %), periferna nevropatija
Each ml of concentrate contains 20 mg docetaxel (as trihydrate). 
En ml koncentrata vsebuje 20 mg docetaksela (v obliki trihidrata).
In study TAX316 alopecia persisting into the follow-up period after the end of chemotherapy was reported in 687 of 744 TAC patients (92.3%) and 645 of 736 FAC patients (87.6%). 
V študiji TAX316 je alopecija trajala še naprej v obdobju spremljanja po koncu kemoterapije pri 687 od 744 bolnic, ki so prejemale TAC (92,3 %), in pri 645 od 736 bolnic, ki so prejemale FAC (87,6 %).
For more details see summary of product characteristics of trastuzumab. 
Za nadaljnje podrobnosti prosimo, glejte povzetek glavnih značilnosti trastuzumaba.
One large randomized phase III study, involving 429 previously untreated patients with metastatic disease, has been performed with doxorubicin (50 mg/m²) in combination with docetaxel (75 mg/m²) (AT arm) versus doxorubicin (60 mg/m²) in combination with cyclophosphamide (600 mg/m²) (AC arm). 
Zdravilo Taxespira v kombinaciji z doksorubicinom Opravljena je bila ena velika randomizirana študija III. faze, ki je vključevala 429 predhodno nezdravljenih bolnic z metastatsko boleznijo; v njej so kombinacijo doksorubicina (50 mg/m2) in docetaksela (75 mg/m 2) (krak AT) primerjali s kombinacijo doksorubicina (60 mg/m 2) in ciklofosfamida
Adjuvant radiation therapy was administered according to guidelines in place at participating institutions and was given to 57.3 % of patients who received TAC and 51.2 % of patients who received FAC. 
Dobilo jo je 57,3% bolnic, ki so prejemale TAC, in 51,2% bolnic, ki so prejemale FAC.
Alopecia; Nail disorders (severe: 0.4%); Skin reaction (no severe) 
Bolezni kože in podkožja alopecija, spremembe nohtov (hude 0,4 %), kožna reakcija (nobene hude)
• pulmonary fibrosis (scarring and thickening in the lungs with shortness of breath) 
• plučna fibroza (brazgotinjenjein zadebelitve v pljučih, težko dihanje/kratkasapa)
A total of 445 patients with KPS >70 were treated with either docetaxel (T) (75 mg/m2 on day 1) in combination with cisplatin (C) (75 mg/m2 on day 1) and 5-fluorouracil (F) 
Skupaj je bilo zdravljenih 445 bolnikov z oceno zmogljivosti po Karnofskem > 70; prejemali so bodisi docetaksel (T) (75 mg/m2 1. dan) v kombinaciji s cisplatinom (C) (75 mg/m2 1. dan)
General Docetaxel should be administered when the neutrophil count is ≥1,500 cells/mm 
Splošno Docetaksel je treba aplicirati, ko je število nevtrofilcev ≥ 1.500 celic/mm
120mg/6 ml contains 6 ml of concentrate. 
120 mg/6 ml vsebuje 6 ml koncentrata.
Tabulated list of adverse reactions in breast cancer for adjuvant therapy with Taxespira 75 mg/m² in combination with doxorubicin and cyclophosphamide in patients with node-positive (TAX 316) and node-negative (GEICAM 9805) breast cancer - pooled data 
Tabelarični prikaz neželenih učinkov adjuvantnega zdravljenja z zdravilom Taxespira 75 mg/m2 v kombinaciji z doksorubicinom in ciklofosfamidom pri bolnicah z rakom dojke s pozitivnimi bezgavkami (TAX 316) in negativnimi bezgavkami (GEICAM 9805) - kumulativni podatki
There was an increased incidence of SAEs (40% vs. 31%) and Grade 4 AEs (34% vs. 23%) in the trastuzumab combination arm compared to docetaxel monotherapy. 
V kombinacijski roki s trastuzumabom je prišlo do povečane incidence resnih neželenih učinkov (40 % proti 31 %) in neželenih učinkov stopnje 4 (34 % proti 23 %) v primerjavi z monoterapijo z docetakselom.
This is equivalent to 60 ml of beer or 25 ml of wine. 
To ustreza 60 ml piva ali 25 ml vina.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm. Efficacy endpoints for the docetaxel arms versus the control arm are summarized in the following table: 
Povečanje v preživetju opazovano pri roki tedenskega docetaksela ni bilo statistično značilno v primerjavi z mitoksantronovo kontrolno roko zdravljenja.
This is equivalent to 70 ml of beer or 29 ml of wine. 
To ustreza 70 ml piva ali 29 ml vina.
Abdominal pain upper; Dry mouth 
Bolezni prebavil bolečine v zgornjem delu trebuha, suha usta
• pain in the joints or muscles 
• občutek omrtvelosti,mravljinčenjeali bolečine v sklepih ali mišicah
MedDRA System Organ classes 
Organski sistemi po MedDRA
This regimen is administered every 3 weeks for 4 cycles. 
Ta terapevtska shema se uporablja vsake 3 tedne po 4 cikluse.
Efficacy of docetaxel in the treatment of patients with gastric adenocarcinoma 
Učinkovitost docetaksela pri zdravljenju bolnikov z adenokarcinomom želodca končna točka
• indigestion 
• nespečnost
Each ml of solution contains 20 mg of docetaxel (as trihydrate). 
En ml raztopine vsebuje 20 mg docetaksela (v obliki trihidrata).
Hypotension; Hypertension; Haemorrhage 
Žilne bolezni hipotenzija, hipertenzija, krvavitev